Возможности спирамицина в современной гинекологической практике

1. Бутранова О.И., Зырянов С.К., Абрамова А.А. Спирамицин: прошлое и будущее антибиотика с плейотропными эффектами в терапии внебольничных инфекций. Фармация и фармакология. 2024; 12(2): 150-71. 
2. Franco P.S., Gomes A.O., Barbosa B.F., Angeloni M.B., Silva N.M., Teixeira-Carvalho A. et al. Azithromycin and spiramycin induce anti-inflammatory response in human trophoblastic (BeWo) cells infected by toxoplasma gondii but are able to control infection. Placenta. 2011; 32(11): 838-44. https://dx.doi.org/10.1016/j.placenta.2011.08.012
3. Montoya J.G., Remington J.S. Management of toxoplasma gondii infection during pregnancy. Clin. Infect. Dis. 2008; 47(4): 554-66. https://dx.doi.org/10.1086/590149
4. Dunn D., Wallon M., Peyron F., Petersen E., Peckham C., Gilbert R. Mother-to- child transmission of toxoplasmosis: risk estimates for clinical counselling. Lancet. 1999; 353(9167): 1829-33. https://dx.doi.org/10.1016/S0140-6736(98)08220-8
5. Rabilloud M., Wallon M., Peyron F. In utero and at birth diagnosis of congenital toxoplasmosis: use of likelihood ratios for clinical management. Pediatr. Infect. Dis. J. 2010; 29(5): 421-5. https://dx.doi.org/10.1097/INF.0b013e3181c80493
6. Wallon M., Peyron F. Effect of antenatal treatment on the severity of congenital toxoplasmosis. Clin. Infect. Dis. 2016; 62(6): 811-2. https://dx.doi.org/10.1093/cid/civ1035
7. Prusa A.R., Kasper D.C., Pollak A., Gleiss A., Waldhoer T., Hayde M. The Austrian toxoplasmosis register, 1992–2008. Clin. Infect. Dis. 2015; 60(2): e4-10. https://dx.doi.org/10.1093/cid/ciu724
8. Wei H.X., Wei S.S., Lindsay D.S., Peng H.J. A Systematic review and meta-analysis of the efficacy of anti-toxoplasma gondii medicines in humans. PLOS One. 2015; 10(9): e0138204. https://dx.doi.org/10.1371/journal.pone.0138204
9. Kang J.K., Kang H.K., Hyun C.G. Anti-inflammatory effects of spiramycin in LPS-activated RAW 264.7 macrophages. Molecules. 2022; 27(10): 3202. https://dx.doi.org/10.3390/molecules27103202
10. Omura S., Sano H., Sunazuka T. Structure activity relationships of spiramycins. J. Antimicrob. Chemother. 1985; 16(Suppl. A): 1-11. https://dx.doi.org/10.1093/jac/16.suppl_a.1
11. Moffat A.C., Osselton M.D., Widdop B., eds. Clarke’s analysis of drugs and poisons. Vol. 2. 3rd ed. London, UK: Pharmaceutical Press, 2004. 1248 p.
12. Montoya J.G., Laessig K., Fazeli M.S., Siliman G., Yoon S.S., Drake-Shanahan E. et al. A fresh look at the role of spiramycin in preventing a neglected disease: meta-analyses of observational studies. Eur. J. Med. Res. 2021; 26(1): 143. https://dx.doi.org/10.1186/s40001-021-00606-7
13. Elazab S.T., Elshater N.S., Hashem Y.H., Al-Atfeehy N.M., Lee E.B.,Park S.C. et al. Pharmacokinetic / Pharmacodynamic modeling of spiramycin against mycoplasma synoviae in chickens. Pathogens. 2021; 10(10): 1238. https://dx.doi.org/10.3390/pathogens10101238
14. Zahari N.I.N., Engku Abd Rahman E.N.S., Irekeola A.A., Ahmed N., Rabaan A.A., Alotaibi J. et al. A review of the resistance mechanisms for β-lactams, macrolides and fluoroquinolones among streptococcus pneumoniae. Medicina (Kaunas). 2023; 59(11): 1927. https://dx.doi.org/10.3390/medicina59111927
15. Громова О.А., Торшин И.Ю. Хемоинформационное исследование спирамицина в сравнении с другими антибиотиками. Фармакоэкономика. Современная фармакоэкономика и фармакоэпидемиология. 2025; 18(1): 80-94. [Gromovа O.A., Torshin I.Yu. Chemoinformatic study of spiramycin in comparison with other antibiotics. Farmakoekonomika. Modern pharmacoeconomics and pharmacoepidemiology. 2025; 18(1): 80-94 (in Russian). https://dx.doi.org/10.17749/2070-4909/farmakoekonomika.2025.296
16. Cornelisse V.J., Sherman C.J., Hocking J.S., Williams H., Zhang L.,Chen M.Y. et al. Concordance of chlamydia infections of the rectum and urethra in same-sex male partnerships: a cross-sectional analysis. BMC Infect. Dis. 2017; 17(1): 22. https://dx.doi.org/10.1186/s12879-016-2141-7
17. Тютюнник В.Л., Михайлова О.И., Кан Н.Е., Мирзабекова Д.Д. Современные представления терапии урогенитального хламидиоза при беременности. Акушерство и гинекология. 2024; 4: 148-54. 
18. Doernberg S.B., Komarow L., Tran T.T.T., Sund Z., Pandori M.W., Jensen D. et al. Simultaneous evaluation of diagnostic assays for pharyngeal and rectal neisseria gonorrhoeae and chlamydia trachomatis using a master protocol. Clin. Infect. Dis. 2020; 71(9): 2314-22. https://dx.doi.org/10.1093/cid/ciz1105
19. CDC. Chlamydial Infections. Chlamydial infection among adolescents and adults. Available at: https://www.cdc.gov/std/treatment-guidelines/chlamydia.htm#print
20. Workowski K.A., Bachmann L.H., Chan P.A., Johnston C.M., Johnston C., Muzny C.A. Sexually transmitted infections treatment guidelines, 2021. MMWR Recomm. Rep. 2021; 70(4): 1-187. https://dx.doi.org/10.15585/mmwr.rr7004a1
21. Ковалёва И.В. Клинические рекомендации по антибактериальной терапии внебольничных инфекций: на что обратить внимание практическому врачу? Лечащий Врач. 2025; 5(29): 59-64. 
22. Довлетханова Э.Р., Абакарова П.Р. Антибактериальная терапия при воспалительных заболеваниях органов малого таза: современные тенденции. Акушерство и гинекология. 2024; 12: 176-84. 

Поступила 25.08.2025

Принята в печать 01.10.2025